Navigation Links
PharmAthene Reports Third Quarter 2010 Financial and Operational Results
Date:11/11/2010

ANNAPOLIS, Md., Nov. 11, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2010.

For the third quarter of 2010, PharmAthene recognized revenues of $6.2 million compared to $6.8 million in the same period of 2009.  For the nine months ended September 30, 2010 and 2009, respectively, PharmAthene recognized revenues of $14.1 million and $20.4 million.  Revenues for the most recent quarter and nine months ended September 30, 2010 consisted primarily of contract funding from the U.S. government for the development of SparVax™, Valortim®, and  Protexia®.

The decline in revenue in the third quarter and first nine months of 2010 compared to 2009 is attributable to (i) the completion of activities under the Company's existing Department of Defense (DoD) contract for Protexia®, which concluded in the third quarter of 2009, partially offset by modest funding from the DoD for this program in the second and third quarters of 2010, and (ii) reduced activity in the Company's Valortim® program, (iii) the completion of all activities in the Company's plague program during early 2010, (iv) partially offset by increased revenues under the Company's SparVax™ program.

Research and development expenses were $6.2 million and $7.9 million for the quarter ended September 30, 2010 and 2009, respectively.  Research and development expenses were $17.1 million and $23.9 million for the nine months ended September 30, 2010 and 2009, respectively.  

Research and development expenses decreased in the third quarter and first nine months of 2010 compared to the prior year period as a result of decreased activity in
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
2. PharmAthene Announces Pricing of $15 Million Public Offering
3. PharmAthene Announces Proposed Common Stock Offering
4. PharmAthene Announces $3.9 Million Registered Direct Offering
5. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
6. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
7. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
8. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
9. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
10. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
11. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... Alternative Fuels Americas, Inc. (AFAI) announced today that ... Vehicle in partnership with Jatro Greentech, Inc., a ... SPV shall be called AFAI Jatro Green Ethiopia and will ... The SPV shall pursue Jatropha planting and biofuels production projects ... . "Although we have experienced great ...
(Date:9/17/2014)... Beckman Coulter , a global ... has renewed its agreement with Personify for ... agreement, Personify will continue to streamline the Beckman Coulter ... analytics, including time-to-fill, time-to-source and a deep reduction to ... Personify was based on the success of our partnership ...
(Date:9/17/2014)... 2014 The Alliance for ... multi-stakeholder non-profit collaborative building a global system to ... today announced Phase 3 of its Site Accreditation ... Amir H. Kalali, Vice-President, Global Head, Neuroscience Center ... Compliance and Quality Integration (CQI) Consulting will lead ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... N.J., Aug. 13 Soligenix, Inc. (OTC Bulletin ... press release contains forward-looking statements that reflect Soligenix, ... prospects and opportunities. Statements that are not historical ... expressions, are forward-looking statements. These statements are subject ...
... have fashioned nanowires into a new type of V-shaped transistor ... interior of cells. The new device, described this week ... viruses and about one-hundredth the width of the probes now ... large as the cells themselves. Its slenderness is a marked ...
... of Calgary, Faculty of Medicine scientists who proved it is ... on a silicon chip or the brain on a ... technology that monitors brain cell activity at a resolution never ... Canada (NRC), the new silicon chips are also simpler to ...
Cached Biology Technology:Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments 2New nanoscale transistors allow sensitive probing inside cells 2Neurochip technology developed by Canadian team 2
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
(Date:9/16/2014)... (September 17, 2014)The North American Menopause Society (NAMS) ... comprehensive care of midlife womenon everything from hot ... North American Menopause Society Recommendations for Clinical Care ... the Society,s journal Menopause . This is ... the care of midlife women freely available to ...
(Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3
... was identified by ancient Egyptians. Genetic analysis done by ... the animal,s range and including DNA from mummified crocodile remains ... name., "This paper provides a remarkable surprise: the Nile crocodile ... demonstrates two species - living side-by side - constitute what ...
... Bone marrow-derived stem cells (BMDCs) have been recognized as ... cell populations in a variety of organs under both normal ... repairing damaged brain tissue or helping to restore lost neural ... cerebellum at the back of the brain. In a recent ...
... Webb from the School of Chemical Engineering and Analytical ... and Excellence Award for Bioprocessing. They received the ... co-production of fuels and chemicals: The biochemical production of ... place last month at the ICC in Birmingham. ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2Award success for University 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: